Healthpeak's High Yield Belies Lab Volatility and Slowing Growth

What happened

A Seeking Alpha article advocates buying Healthpeak Properties for its 7.16% yield and undervaluation, citing the REIT's shift to labs and outpatient medical buildings. DeepValue's analysis confirms this strategic pivot but reveals it has heightened capital intensity and AFFO volatility, with Q3 2025 results showing a net loss from $169 million in lab JV impairments. Total same-store NOI growth slowed to 0.9% in that quarter, dragged down by lab oversupply and weak biopharma funding, despite resilient outpatient and CCRC segments. The market narrative understates lab cyclicality and rising interest expense, yet the stock at $16.71 trades near 9x 2025 FFO, discounting much of this risk. While the covered 7.3% dividend offers income, investors face a reality of limited FFO growth and ongoing balance sheet pressures from higher borrowing costs.

Implication

The 7.3% dividend yield provides steady income, but with FFO growth projected at 0-2%, total returns will rely heavily on yield rather than appreciation. Lab segment weaknesses, evidenced by impairments and occupancy declines, pose a material threat to AFFO and could trigger further valuation compression if biopharma funding does not recover. Outpatient and CCRC operations offer stability, but may not fully offset lab headwinds, emphasizing the need for diversified exposure within healthcare REITs. Management's execution on asset sales and leverage control is critical to maintain investment-grade ratings and avoid dividend cuts. For contrarian buyers, entry near $16.00 offers value, but positions should be sized cautiously with exit triggers based on lab occupancy falling below 80% or AFFO payout rising above 80%.

Thesis delta

The Seeking Alpha article reinforces DeepValue's cautious stance, highlighting limited AFFO growth of 0-2% that aligns with the base case of slow, stable expansion. It adds no new data but underscores the earnings compression and capital intensity risks from the lab shift, validating the report's emphasis on lab cyclicality. No material shift occurs; the thesis remains that DOC is a potential buy at discounted levels if outpatient resilience persists and lab headwinds are contained, but with heightened scrutiny required.